Pediatric Soft Tissue Sarcomas
Copyright policy )Pediatric Soft Tissue Sarcomas
Soft tissue sarcomas in children are rare. Approximately 850 to 900 children and adolescents are diagnosed each year with rhabdomyosarcoma (RMS) or a non-RMS soft tissue sarcoma (NRSTS). RMS is more common in children 14 years old and younger and NRSTS in adolescents and young adults. Infants get NRSTS, but their tumors constitute a distinctive set of histologies. Surgery is a major therapeutic modality and radiation plays a role. RMS is treated with adjuvant chemotherapy, whereas chemotherapy is reserved for the NRSTS that are high grade or unresectable. This review discusses the etiology, biology, and treatment of pediatric soft tissue sarcomas.
- Johns Hopkins University United States
- Johns Hopkins Medicine United States
- Sidney Kimmel Comprehensive Cancer Center United States
Rhabdomyosarcoma, Humans, Radiotherapy Dosage, Rhabdomyosarcoma, Embryonal, Soft Tissue Neoplasms, Child, Neoplasm Staging
Rhabdomyosarcoma, Humans, Radiotherapy Dosage, Rhabdomyosarcoma, Embryonal, Soft Tissue Neoplasms, Child, Neoplasm Staging
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).109 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!